ETON
Research Snapshot
Static fundamentals, valuation context, and investor signals for Eton Pharmaceuticals, Inc. (ETON).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-17.6%
ROIC, 12.7% FCF margin
Growth
359.6%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 1.6x current ratio
Superinvestors
1
Top: Polen Capital Management (0.0%)
Strengths to research
- Revenue compounded at 359.6% over five years.
- Free cash flow margin is healthy at 12.7%.
- Debt/equity looks manageable at 0.0x.
- 8 annual periods are available for trend analysis.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 8 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ETON.
Grade D
26
/ 100
Financial Charts
No financial data available for ETON (annual).
1 superinvestors own ETON
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 30,138 | $744,000 | 0.01% | 0.0% |